Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 3/20 | 0.32 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30503535 | 1.00 | DGAT1 (0.32) | DGAT1ACACBABHD6FAAHMGLL | |
| SCHEMBL26631467 | 0.86 | DGAT1 (0.43) | DGAT1ACACBABHD6FAAHMGLL | |
| SCHEMBL29427009 | 0.86 | DGAT1 (0.43) | DGAT1ACACBABHD6FAAHMGLL | |
| SCHEMBL26631355 | 0.86 | FFAR4 (0.32) | DGAT1ACACBABHD6FAAHMGLL | |
| SCHEMBL26631338 | 0.85 | ACACB (0.34) | DGAT1ACACBABHD6FAAHMGLL | |
| SCHEMBL30503541 | 0.81 | DGAT1 (0.37) | DGAT1ACACBIKBKB | |
| SCHEMBL26631319 | 0.81 | DGAT1 (0.37) | DGAT1ACACBIKBKB | |
| SCHEMBL25410957 | 0.78 | FFAR4 (0.31) | ACACBABHD6FAAHMGLL | |
| SCHEMBL25434328 | 0.78 | ACACB (0.34) | DGAT1ACACBABHD6FAAHMGLL | |
| SCHEMBL25411789 | 0.75 | GPR183 (0.37) | DGAT1ABHD6FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-06-27 | — | — | US | disclosed |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-31 | — | — | US | disclosed |
| EP-4217062-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN Pharmaceutica NV (BE) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208902-A1 | CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | DGAT1 70/4885ACACB 61/4885ABHD6 25/4885 |
| US-11802111-B2 | Cyclobutyl amide monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | DGAT1 67/4885ACACB 60/4885ABHD6 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.